- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Avalon GloboCare Corp.: Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference | 1 | GlobeNewswire (USA) | ||
| 15.04. | Avalon GloboCare Corp. - 10-K, Annual Report | 1 | SEC Filings | ||
| 01.04. | Avalon GloboCare Corp. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 28.03. | Avalon GloboCare Corp.: Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union | 1 | GlobeNewswire (USA) | ||
| 27.03. | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 3 | 4.113 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameUS00941Q2030 AIRNET... ► Artikel lesen | |
| 18.12.23 | Avalon GloboCare Corp.: Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US | 1 | GlobeNewswire (USA) | ||
| 22.11.23 | Avalon GloboCare Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.23 | Avalon GloboCare Corp. - 10-Q, Quarterly Report | - | SEC Filings |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 460,90 | -1,24 % | Deutliches Plus erfreut Inhaber der IDEXX Laboratories-Aktie (520,9077 €) | Grund zur Freude haben Anleger, die in den Anteilsschein von IDEXX Laboratories investiert haben: Der Kurs der Aktie legt kräftig zu. Eine Steigerung um 6,04 Prozent - mit diesem Wertanstieg gehört... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,384 | -2,30 % | BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting | Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 7,215 | +1,26 % | Voyager Therapeutics, Inc.: Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting | ||
| ADAPTIMMUNE THERAPEUTICS | 1,030 | +3,00 % | Adaptimmune Therapeutics PLC: Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated | Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchiseUpdate on afami-cel launch plans to be provided at the April... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,286 | +2,34 % | Anavex Life Sciences Corp.: Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia | First patient screened ahead of schedule Trial to investigate positive, negative, and cognitive domains of schizophrenia ANAVEX®3-71's differentiated dual novel mechanism of action offers the potential... ► Artikel lesen | |
| LUMOS PHARMA | 2,825 | +0,89 % | LUMOS PHARMA, INC. - 10-K/A, Annual Report | ||
| ZYMEWORKS | 7,450 | -5,70 % | Zymeworks Inc.: Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting | VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 0,840 | 0,00 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results | Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 9,500 | +7,34 % | Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy | Data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS' ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing
... ► Artikel lesen | |
| VTV THERAPEUTICS | 9,500 | 0,00 % | vTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update | Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy... ► Artikel lesen | |
| CELLAVISION | 19,660 | -3,39 % | CellaVision AB: A Solid Start to the Year | Organic sales growth:Q1, 2024: 22% (-21)EBITDA margin:Q1, 2024: 29% (25)January 1 - March 31, 2024Net sales increased by 22% (-14) to SEK 170 m (139).Sales increased organically by 22% (-21), currency... ► Artikel lesen | |
| NUVATION BIO | 2,675 | +1,90 % | Nuvation Bio Completes Acquisition of AnHeart Therapeutics | NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and... ► Artikel lesen | |
| BIONOMICS | 0,605 | +4,31 % | Bionomics Ltd: Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder | BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over... ► Artikel lesen | |
| ONCONETIX | 0,105 | +5,00 % | Onconetix, Inc. - S-1/A, General form for registration of securities | ||
| CLENE | 0,322 | +1,90 % | Clene Inc. - 8-K, Current Report |
AVALON GLOBOCARE CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,279 Euro und damit +1,38 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
